NASDAQ:PYXS Pyxis Oncology Q3 2025 Earnings Report $2.14 -0.05 (-2.28%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$2.15 +0.01 (+0.28%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pyxis Oncology EPS ResultsActual EPS-$0.35Consensus EPS -$0.36Beat/MissBeat by +$0.01One Year Ago EPSN/APyxis Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APyxis Oncology Announcement DetailsQuarterQ3 2025Date11/3/2025TimeBefore Market OpensConference Call DateMonday, November 3, 2025Conference Call Time4:00PM ETUpcoming EarningsPyxis Oncology's Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Pyxis Oncology Earnings HeadlinesPyxis Oncology Closes $110 Million Public Offering to Advance MICVO Clinical DevelopmentOctober 2 at 7:11 AM | quiverquant.comQPyxis Oncology Announces Closing of Up to $282.6 Million Public OfferingOctober 2 at 7:00 AM | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)Comparing Pyxis Oncology (NASDAQ:PYXS) & Inovio Pharmaceuticals (NASDAQ:INO)October 1 at 4:15 AM | americanbankingnews.comPyxis Prices $110 Mln Offering, With Potential Proceeds Of $282 Mln To Advance Lead Cancer DrugSeptember 30 at 11:20 AM | rttnews.comBiggest stock movers Wednesday: BA, PYXS, NOC, and moreSeptember 30 at 6:19 AM | msn.comSee More Pyxis Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email. Email Address About Pyxis OncologyPyxis Oncology (NASDAQ:PYXS) (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing therapies for patients with cancer. The company’s approach is centered on creating antibody-based medicines designed to selectively target tumor cells or the tumor microenvironment while delivering therapeutic activity intended to improve cancer treatment outcomes. Pyxis Oncology’s pipeline has included PYX-201, an antibody-drug conjugate designed to target extra-domain B fibronectin, a protein associated with the tumor microenvironment, and PYX-106, an investigational antibody targeting SIGLEC-15, an immune-regulatory protein expressed in several cancers. These programs have been evaluated in clinical studies across solid-tumor indications, with development priorities subject to the company’s ongoing research and clinical results. The company was established to develop novel oncology treatments and is headquartered in Boston, Massachusetts. Its work is primarily focused on advancing investigational medicines through clinical development for potential use in the United States and broader international cancer-treatment markets. Pyxis Oncology is led by Lara Sullivan, M.D., who serves as president and chief executive officer.View Pyxis Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
